A multicenter, double-blind, placebo-controlled, randomized study drug Runihol® in patients with nonalcoholic fatty liver disease and metabolic syndrome
Phase of Trial: Phase II
Latest Information Update: 23 Jan 2018
At a glance
- Drugs Inosine (Primary)
- Indications Liver disorders; Non-alcoholic fatty liver disease
- Focus Therapeutic Use
- Sponsors POLYSAN
- 16 Jan 2018 Planned End Date changed from 1 Nov 2017 to 1 Nov 2020.
- 16 Jan 2018 Planned primary completion date changed from 1 Aug 2017 to 1 Aug 2020.
- 10 Jun 2017 Biomarkers information updated